Myriad Genetics, Inc. has received $0.24 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 9 Financial Advisor in the Stock Trading Firms. Among 9 Analysts, Bottom line EPS Estimate for the current quarter is $0.22 while the top line estimate is $0.25 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -47.16%.
Myriad Genetics, Inc. results fell short with a surprise EPS of -11.54% or $-0.03. The Actual EPS was $0.23 compared to the Estimated EPS of $0.26 during its most recent quarterly earnings. Salt Lake City based Myriad Genetics, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 07, 2017.
Myriad Genetics, Inc. has a Price to Earnings ratio of 10.7 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 1.45. For the Most Recent Fiscal Year, Myriad Genetics, Inc. has a price to cash ratio of 7.47. For the Trailing twelve month period, company showed a Net Profit Margin of 11.38% and Return on Equity of the stock is 13.98%.
In the last quarter, Myriad Genetics, Inc. reported Annual Earnings of $0.23. Based on the filings, last years Annual Earnings was, $1.63. In the last Quarter, MYGN reported a surprise Earnings per Share of -11.54% . The consensus estimate for current quarter is $0.24 and for the current fiscal year, the estimate is $0.99. For the Next fiscal year, the estimate is $1.05 based on the consensus.
Myriad Genetics, Inc. (NASDAQ:MYGN) : On Tuesday heightened volatility was witnessed in Myriad Genetics, Inc. (NASDAQ:MYGN) which led to swings in the share price. The stock opened for trading at $15.45 and hit $16.33 on the upside , eventually ending the session at $16.18, with a gain of 4.32% or 0.67 points. The heightened volatility saw the trading volume jump to 1,514,092 shares. The 52-week high of the share price is $39.82 and the company has a market cap of $1,107 million. The 52-week low of the share price is at $15.36 .
Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.